新冠疫苗企业传奇创始人夫妇双双“出走”，将开启第三次创业

Core Viewpoint - BioNTech's co-founders, Ugur Sahin and Oezlem Tuereci, announced their departure from the company in 2026, leading to a nearly 18% drop in stock price, marking the lowest point since August 2024, with a current market value of approximately $22 billion [2]. Group 1: Company Leadership Transition - BioNTech is actively seeking successors to ensure a smooth transition following the departure of its founders [2]. - The founders plan to establish a new company, but they assure that BioNTech's research pipeline will remain unaffected by their exit [3]. Group 2: Financial Performance and Market Position - BioNTech's peak market value reached around $200 billion during the pandemic, but sales of COVID-19 vaccines have significantly declined post-pandemic [2]. - The company is shifting its focus towards the development of mRNA cancer vaccines, with potential market entry expected around 2030 [2]. Group 3: Strategic Partnerships and Collaborations - BioNTech has formed partnerships with several Chinese biotech firms, including a notable acquisition of Pumice Biotech, which led to a $10 billion licensing deal with Bristol-Myers Squibb [3]. - The company has also engaged in multiple licensing agreements in the oncology sector, with total deal sizes ranging from $1 billion to $2 billion [3]. Group 4: Personal Wealth and Compensation - Sahin's compensation in 2024 from exercising stock options amounted to €260 million (approximately ¥2 billion), making him one of the highest-paid executives in the pharmaceutical industry that year [3]. - As of now, Sahin's net worth is estimated at $3.6 billion (approximately ¥24.7 billion), a significant decrease from $11.3 billion (approximately ¥77.6 billion) in early 2022 [4].